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INTRODUCTION: Since 1999, the Ministry of Health in Brazil has conducted campaigns of vaccination against influenza
targeted towards the elderly, chronically-diseased people and health care workers. The vaccine against influenza is associated
with adverse events of minor importance.
OBJECTIVE: To investigate the early adverse events related to the vaccine against influenza.
CASUISTICS AND METHODS: One hundred and ninety seven elderly individuals and health care workers vaccinated against
influenza were included. An inquiry regarding adverse events related to the vaccine was applied seven days after the vaccination.
RESULTS: Local adverse events were reported by 32.5% and systemic effects by 26.4% of the vaccinated subjects. Pain in the
region of the injection, headache, myalgia, malaise, and coryza were more frequent in the workers than in the elderly (p<0.05).
There was no statistically significant difference in the occurrence of fever.
CONCLUSIONS: The belief of part of the population that credits frequent and uncomfortable adverse events to the vaccine was
not confirmed. The subjective adverse events were more frequent in the health care workers, which can influence, in a negative
way, the disclosure of the benefits of this vaccine due to their role as opinion makers.
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INTRODUCTION
Influenza is an acute respiratory disease that is auto-
limited and caused by Orthomyxovirus, predominantly the
A, B and C types. It is highly contagious, and infects a great
number of individuals in a short period of time. In regions
of cold and mild weather, the infections are more frequent
during the winter months. Although some authors believe
there is evidence of influenza epidemics dating back to
1510,1 studies with serologic evidence became possible due
to the isolation of the virus in 1933.2
The Influenza viruses, mainly the A type, acquire fre-
quent antigenic variations. The smaller variations, known
as “antigenic drifts”, occur approximately each year and
are responsible for the epidemics. The larger variations,
“antigenic shifts”, are less frequent and cause the great
pandemics. Between 1977 and 1988, there were seven epi-
demics in the USA, with more than 10,000 deaths, with
around 80% in individuals 65 years of age or older.3 The
deaths, which can occur due to the action of the virus it-
self or are related to a secondary bacterial infection, most
commonly occur in the elderly and individuals with chronic
cardiopulmonary diseases.
The largest impact of influenza epidemics can be ob-
served in terms of morbidity, especially in adults with res-
piratory disease, as infection causes higher hospitalization
rates, increased numbers of ambulatory appointments, and
absenteeism in work and school.
The use of vaccines of inactivated viruses since the mid-
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dle of the 1940’s constitutes an important public health
measure in order to reduce the occurrence of influenza and
minimize its consequences.
Since 1948, the World Health Organization (WHO),
through the Influenza Prevention Program, has coordinated
a net of laboratories responsible for the surveillance and
identification of the virus isolated in different continents.
To date, the composition of the vaccine against influenza
has been preconized and recommended for annual use dur-
ing the autumn months in the north hemisphere.
Since 2000, the Ministry of Health in Brazil has im-
plemented the System of Surveillance of Influenza. The
system is designed to: perform viral monitoring, evaluate
the impact of vaccination, and follow the tendencies of
morbidity and mortality through a sentinel surveillance
strategy involving health unities and diagnostic laborato-
ries.4
Many studies, mainly conducted in the Northern hemi-
sphere, have evaluated the efficiency of the influenza vac-
cine, and have shown that the effectiveness of the vaccine
in the reduction of severe disease, hospitalization, pneu-
monia, and death is superior (47 to 95%)5,6,7,8 to the reduc-
tion of the influenza occurrence (around 30%).9 Although
the effectiveness of influenza vaccination has not been ex-
tensively studied in Brazil, some Brazilian regional stud-
ies show that it is effective.10 Gross and collaborators, in a
meta analysis evaluating 20 studies, verified that the in-
fluenza vaccine had the capacity of preventing hospitali-
zation due to pneumonia in 32 to 45% of the elderly, to
prevent death due to pneumonia and influenza in 31 to 65%
of the elderly, and prevent death due to any cause in 27 to
30%.11 A systematic review of the efficacy and effective-
ness of the Influenza vaccine in the elderly concluded that
well matched vaccines prevented hospital admission for
influenza and pneumonia, mainly in long-term health fa-
cilities.12 In Brazil, the influenza vaccine has been freely
distributed by the public health system since 1999. Its cov-
erage in the elderly from 2000 to 2005 in the Southeast
and Southern regions was almost always inferior to the cov-
erage in Brazil. In 2006, the vaccine coverage in the state
of São Paulo was 80.2%, the lowest in the Southeast re-
gion, while the coverage reached 85.7% in Brazil.13
This fact is paradoxical since the state of São Paulo has
an adequately installed public health system and presents
elevated vaccination routine coverage in other age groups.
One of the factors that can contribute to this situation is
the fear of adverse events related to this vaccine. Empiri-
cally, it is observed that the lay population, particularly the
elderly and health care workers (HCW), associate several
morbid states with the influenza vaccine and express a lot
of uncertainty about its role in preventing influenza, which
can contribute to lower adherence to the vaccination cam-
paigns.
Analysis of the literature shows that the local reactions
to the inactivated virus influenza vaccine are the most fre-
quent. Erythema, pain, and edema in the region of the in-
jection can occur around 12 to 24 hours after the vaccina-
tion. They are more frequent in adults and occur in 10%
to 64% of individuals who are vaccinated. The systemic
reactions in adults include fever, myalgia, arthralgia, head-
ache, malaise, and lack of respiratory symptoms. They can
appear in the first seven days after the vaccination and vary
from less than 1% to 18.9%, with an average of 10%.1
Although some neurological syndromes have been tem-
porarily associated with the inactivated virus in the influ-
enza vaccine, only Guillain-Barré syndrome was clearly
associated with the swine virus vaccine used in 1976.14 In
most recent years, it has been speculated that the reports
of Guillain-Barré syndrome after influenza vaccination
were not coincidental. Additional studies are necessary in
order to investigate the possible relation between this syn-
drome and the influenza vaccine.15
Immediate hypersensitive reactions, such as
angioedema, allergic asthma, or anaphylactic reaction, can
rarely occur after influenza vaccination. These manifesta-
tions probably result from hypersensitivity to some com-
ponent of the immunogen. The vaccination is only contrain-
dicated in people who have presented severe adverse al-
lergic reactions in previous doses.
The Immunization Center of the Hospital das Clínicas,
São Paulo University Medical School participates in the Na-
tional Vaccination Campaign against influenza, which oc-
curs in the first semester of each year and vaccinates all
individuals according to indications from the Ministry of
Health; the subjects in our study consisted of a
subpopulation of this cohort. Our study subjects were in-
dividuals aged 60 years or older and the health care work-
ers (HCW) that had contact with elderly and immuno-de-
pressed patients. The objective of this study was to con-
tribute to the clarification of the causes related to the low
coverage verified in the State of São Paulo by evaluating
the occurrence of adverse events related to the influenza
vaccine in a sample of the vaccinated population of the
2002 Campaign, constituted of elderly and HCW from the
Hospital das Clínicas, São Paulo University Medical
School.
OBJECTIVE
To investigate the occurrence of early adverse events
(AE) after influenza vaccination.
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CASUISTIC AND METHODS
For the calculation of the sample, the program Statcalc
- EpiInfo version 6.0 was used. It was estimated that in the
year 2002, 4,000 people would be vaccinated. The expected
frequency of adverse events in adults is 10%.16 A sample
of 200 individuals was calculated (confidence interval
[CI=95%]).
The selected population consisted of individuals who
were 60 years of age or older, and the HCW from the Hos-
pital das Clínicas, São Paulo University Medical School,
were vaccinated against influenza at the Immunization
Center of the Hospital das Clínicas, São Paulo University
Medical School from April 13th, 2002.
Inclusion criteria included:
- Elderly population: being 60 years old or older, or
- Health Care Worker population: being an active worker
of the Hospital das Clínicas, São Paulo University Medi-
cal School, belonging to any age group.
When the subjects were 60 years old or more and a
HCW, they were added to the HCW group.
Casuistics selection:
This study was approved by the Ethics Commission for
the Analysis of Research Projects from the Hospital das
Clínicas, São Paulo University Medical School under
number 321/02.
The first 200 people who met the inclusion criteria at
the Immunization Center were contacted by telephone
seven days after the vaccination. All participants included
in the study agreed to answer a standardized inquiry via
telephone.
The statistical analysis was executed by the EpiInfo ver-
sion 6.0 program. In order to evaluate the differences in
proportions, the P values were calculated using χ2 tests. P
<0.05 indicated statistical significance.
RESULTS
From the 200 selected subjects, two were excluded be-
cause they were 59 years old and one because he did not
agree to participate in the interview. From the 197 included,
146 were elderly and 51 were HCWs. In Table 1, the dis-
tribution of the vaccinated subjects by gender is presented.
The average age was 71 years (range: 60 to 90 years)
among the elderly and 38.8 years (18 to 68 years old)
among the HCWs.
The prevalence of previous asthma and bronchitis was
used to characterize the subjects of the study, and it was
not used to indicate AE. There was no statistically signifi-
cant difference in the previous occurrence of asthma and
bronchitis between the elderly and HCW. On the other
hand, previous influenza vaccination was more frequent in
the elderly (Table 2).
Local AE were reported by 32.5% and systemic AE
were reported by 26.4% of the vaccinated. Additionally, we
compared the occurrence of AE between the elderly and
HCWs. The local and systemic AE frequency was more el-
evated among the HCWs than the elderly (P < 0.01).
As shown in Table 3, local AE were significantly more
frequent among the HCWs due to the symptom of pain (P
<0.0001) (Table 3).
Among the investigated systemic AE, headache, myal-
gia, malaise, and coryza were significantly more frequent
in the HCW than the elderly (Table 4). The other investi-
gated events (fever, asthenia, cough, dyspnea, expectora-
tion, arthralgia, bronco spasm, thoracic pain, and rash) oc-
curred in similar frequencies in both groups.
Table 1 - Distribution of individuals vaccinated against
influenza according to gender. Hospital das Clínicas, São
Paulo University Medical School. 2002
Patients Male Female Total
n % n % n %
Elderly 61 41.8 85 58.2 146 74.1
HCW 3 5.9 48 94.1 51 25.9
Total 64 32.5 133 67.5 197 100
HCW - Health Care Workers; n-number; %- percentage
Table 2 - Distribution of individuals vaccinated against
influenza according to previous asthma, bronchitis and
influenza vaccination. Hospital das Clínicas São Paulo
University Medical School. 2002
Variable Elderly HCW P
n % n %
Asthma / bronchitis 11 9.6 2 3.9 0.212
Previous vaccination 126 87.5 30 58.8 < 0.001
HCW – Health Care Workers; n-number; %- percentage
Table 3 - Occurrence of local adverse events after influenza
vaccination. Hospital das Clínicas, São Paulo University
Medical School. 2002
Local AE Elderly HCW Total P
n % n % n %
Total 37 25.3 27 52.9 64 32.5 0.00029
Pain 32 21.9 26 51.0 58 28.8 <0.0001
Erythema 11 7.5 4 7.8 15 7.1 0.9
Edema 13 8.9 6 11.8 19 9.1 0.6
AE – adverse events; HCW – Health Care Workers; n-number; %- percentage
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There was not a statistically significant difference in the
occurrence of local and systemic AE among the individu-
als exclusively vaccinated against influenza and the ones
that received other vaccines concomitantly (Table 5).
DISCUSSION
In this study, the occurrence of early AE after influenza
vaccination was investigated. Although severe AE were not
observed, the obtained frequencies were higher than our
initial estimates, which were based on the existing litera-
ture1. As expected, the HCWs were younger than the eld-
erly. The higher frequency of women among HCWs can
be attributed to the gender distribution observed among
health area workers in general and, in particular, in the Hos-
pital das Clínicas, São Paulo University Medical School,
which shows a predominance of the female gender.
Previous influenza vaccination, respiratory disease, and
concomitant administration of other vaccines were not as-
sociated with local or systemic AE occurrence.
Local AE were more frequent than systemic AE in both
investigated groups. It is noteworthy that AE, both local
and systemic, were more frequent in HCWs than in the eld-
erly.
In relation to local AE, pain, of subjective evaluation,
was the only AE that was significantly more frequent
amongst HCWs. Differences in the occurrence of edema
and erythema, of objective evaluation, were not identified.
Concerning systemic AE, subjective symptoms were
observed among the HCWs more frequently than in the eld-
erly, whereas fever, of objective evaluation, was similar in
both groups. The findings of this study do not confirm the
common belief that credits the influenza vaccine with un-
comfortable and severe adverse events.
This vaccine is effective in the prevention of influenza
in around 90% of healthy young adults and in 30 to 40%
among the elderly when the vaccinal strain is similar to
the circulating strain. Under these circumstances, the vac-
cine is effective in the prevention of complications and
death due to influenza. This effectiveness is not always un-
derstood and assimilated, not only by the lay population,
but also by HCW.
Answering concerns from the target population in re-
lation to the safety and efficacy of the influenza vaccine
depends on ample disclosure of information regarding these
issues, preferably obtained from studies performed in Bra-
zil. Our group has previously conducted investigations on
the effectiveness of the influenza vaccine in the elderly10,
demonstrating a reduction in the amount of flu-like epi-
sodes among the vaccinated.
Taking into consideration the privileged role that HCWs
have in the disclosure of information regarding health, and
their potential influence (which may be negative) concern-
Table 4 - Occurrence of systemic adverse events after influenza vaccination. Hospital das Clínicas, São Paulo University
Medical School. 2002
Systemic AE Elderly HCW Total P
N % N % N %
Total 30 20.5 22 43.1 52 26.4% < 0.01*
Myalgia 12 8.2% 10 19.6% 22 11.2% 0.026*
Asthenia 12 8.2% 8 13.7% 20 9.6% 0.129
Malaise 9 6.2% 9 17.6% 18 9.1% 0.014*
Cough 11 7.5% 6 11.8% 17 8.6% 0.354
Cephalalgia 6 4.1% 10 19.6% 16 8.1% < 0.01*
Coryza 8 5.5% 8 15.7% 16 8.1% 0.022*
Fever 7 4.8% 3 5.9% 10 5.1% 0.761
Dyspnea 4 2.7% 4 7.8% 8 4.1% 0.112
Expectoration 6 4.1% 2 3.9% 8 4.1% 0.953
Arthralgia 6 4.1% 0 0 6 3% 0.141
Bronco spasm 2 1.4% 2 3.9% 4 2% 0.266
Thoracic Pain 2 1.4% 0 0 2 1% 0.405
Asthma 1 0.7% 0 0 1 0.5% 0.553
AE – adverse events; HCW – Health Care Workers; n-number; %- percentage
Table 5 - Occurrence of local and systemic adverse events
after influenza vaccination according to concomitant
administration of other vaccines. Hospital das Clínicas, São
Paulo University Medical School. 2002
AE Concomitant vaccination P
Local Yes No
N % N %
yes 15 27 49 36 0.25
no 40 73 88 64
Systemic
yes 16 29 35 26 0.62
no 39 71 102 74
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ing the revelation of the benefits of this vaccine, we em-
phasize the importance of continuous data collection, as
well as the disclosure of correct health information and re-
sults obtained by HCWs in national and international re-
search as an additional strategy to elevate the influenza vac-
cine coverage rates during the annual vaccination cam-
paigns.
STUDY LIMITATIONS
This study was hindered by the fact that it was origi-
nally planned to detect the occurrence of AE related to the
influenza vaccine in subjects who were presumably healthy.
During the analysis, we detected that AE in HCWs were
more prevalent than in the elderly. The results were vali-
dated by a statistically significant difference between
groups. The authors thus decided to present those results,
considering the role of HCWs from prominent institutions
in influencing people in the community. Future studies spe-
cifically designed for this matter can improve the under-
standing of this subject.
The authors recognize the limitations of the use of in-
formation obtained by telephone interviews. In this study,
we were interested in identifying AE by the words of the
patients, and the telephone interview was a practical, in-
expensive way of obtaining this information.
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